Product category:
Laboratory and scientific manufacturing services
News Release from: PolyPeptide Laboratories
Edited by the Laboratorytalk Editorial
Team on 03 August 2005
Expanding GMP manufacturing in USA and
Sweden
In response to growing demand for therapeutic peptides, PolyPeptide Laboratories has announced plans to substantially increase its manufacturing capabilities in both the USA and Europe.
In response to growing demand for therapeutic peptides, PolyPeptide Laboratories has announced plans to substantially increase its manufacturing capabilities in both the USA and Europe The expansion will take place at two of PolyPeptide Laboratories's GMP manufacturing facilities: Torrance, California, and Malmo, Sweden
This article was originally published on Laboratorytalk on 24 Feb 2003 at 8.00am (UK)
Related stories
First spinal study of bone substitute
Study will measure performance of synthetic bone graft substitute in 30 patients undergoing spinal fusion for degenerative disc disease
Acquisition creates global CRO
Advanced Clinical Sciences becomes a global player in clinical research with the takeover of a Swiss CRO called CRC
The result will be a doubling of the manufacturing capacity in Torrance and substantial increases in the capacity in Malmo.
The expansion plans for both facilities focus mainly on increased capacity for solid-phase peptide manufacturing.
The increase in solid-phase capacity in the Torrance and Malmo facilities serves to complement the large solution-phase synthesis capabilities already present at the PolyPeptide Laboratories facilities in Malmo, Sweden and Hillerod, Denmark.
The decision to expand the facilities in response to the increasing demand from both biotech and pharmaceutical customers for experienced large-scale GMP peptide manufacturing will help to maintain PolyPeptide Laboratories's leading position in this market, the company believes.
The combination of technical know-how, state-of-the-art production facilities and comprehensive regulatory support that PolyPeptide laboratories provides its customers is considered a critical advantage in the competitive drug development arena, and has helped to sustain double digit growth rates for the company, it says.
Both biotech and large pharmaceutical companies have benefited from the experience and knowledge of PolyPeptide Laboratories in the development of their clinical peptide therapeutic compounds.
The new facilities are planned to begin production in 2006.
PolyPeptide Laboratories is a privately owned group of companies focused exclusively on the manufacture of active pharmaceutical ingredients based on peptides.
PolyPeptide Laboratories manufactures both proprietary and generic peptides for the pharmaceutical industry.
• PolyPeptide Laboratories: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
